Products & Services · Maximum funding

ALN-AGT Phase 3 Clinical Trial — Maximum funding

Alnylam Pharmaceuticals ALN-AGT Phase 3 Clinical Trial — Maximum funding increased by 100.0% to $12.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ3 2020
Last reportedQ1 2026
Metric ID: alny_segment_aln_agt_phase_3_clinical_trial_maximum_funding

Historical Data

3 periods
 Q3 '25Q4 '25Q1 '26
Value$18.00M$6.00M$12.00M
QoQ Change—-66.7%+100.0%
Range$6.00M – $18.00M

Frequently Asked Questions

What is Alnylam Pharmaceuticals's aln-agt phase 3 clinical trial — maximum funding?
Alnylam Pharmaceuticals (ALNY) reported aln-agt phase 3 clinical trial — maximum funding of $12.00M in Q1 2026.